Isoliquiritigenin Could Aid Pulmonary Fibrosis Research
A laboratory study found that the compound may protect lung cells from damage, though the findings remain preliminary.
Updated on Oct. 26, 2026 in Asthma
A laboratory study suggests that the compound isoliquiritigenin may help prevent pulmonary fibrosis by inhibiting specific cellular transitions. These findings represent a preliminary step in exploring the potential therapeutic use of this compound for lung health.
Why it matters
Pulmonary fibrosis involves scarring that makes breathing difficult, and identifying new compounds that protect lung cells is a key focus of ongoing respiratory research. This study provides an early look at how isoliquiritigenin might help maintain healthy lung cell function.
In a preclinical study using A549 cells, researchers observed that isoliquiritigenin modulates protein levels associated with fibrosis and improves mitochondrial function. As a preliminary laboratory investigation, the findings have not been tested in human subjects.
The details
Isoliquiritigenin appears to work by promoting Nix-mediated mitophagy, a process where cells clear out damaged mitochondria to maintain energy levels. By improving mitochondrial membrane potential and reducing reactive oxygen species, the compound inhibits the epithelial-mesenchymal transition, a biological process that contributes to tissue scarring in pulmonary fibrosis. Furthermore, researchers found that overexpression of the Nix protein enhanced these protective effects, helping to regulate proteins like E-cadherin and fibronectin.
Timeline
The findings were published on October 26, 2026.
Health Landscape
This research follows the ongoing investigation into TGF-β1-induced epithelial-mesenchymal transition mechanisms, which are central to the development of lung scarring. It sits within a growing body of work exploring plant-derived compounds for their potential to support mitochondrial health.
Because these findings are limited to laboratory cell cultures, they do not currently change clinical practice or treatment options for patients. Any questions about respiratory health or concerns regarding lung scarring should be addressed through a conversation with your physician.
The takeaway
While this study identifies a potential pathway for protecting lung cells, isoliquiritigenin is currently only a candidate agent in preliminary research. Readers should remain cautious of non-clinical findings and continue to discuss any lung health concerns with a medical professional.
Further reading
For more on the current understanding of lung tissue health, visit the Asthma section.
Source note: This article includes information reported by Nature.
